rAAt (inhaled) Arriva/Hyland Immuno.

Arriva Pharmaceuticals Inc and Hyland Immuno are developing a nebulized formulation of the recombinant alpha1-antitrypsin (rAAT) for the potential treatment of respiratory disorders, including emphysema, asthma and chronic obstructive pulmonary disease. The therapy, as a nebulized formulation, is currently undergoing phase II clinical trials.